| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 |
| Sales | 3,000 | 2,290 | 3,400 | 2,970 | 1,490 |
| Sales Growth | +31.00% | -32.65% | +14.48% | +99.33% | unch |
| Net Income | -20,400 | -33,460 | -45,610 | -45,280 | -34,730 |
| Net Income Growth | +39.03% | +26.64% | -0.73% | -30.38% | -252.95% |
Renalytix Plc Sp/Adr (RNLXY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Renalytix plc, formerly known as RENALYTIX AI, is based in NEW YORK.
Fiscal Year End Date: 06/30